Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies modulating the T-type calcium channel (Cav3) for the treatment of neurological and oncologic diseases. Cavion is co-sponsoring a Phase 1 trial of mibefradil combined with hypofractionated radiation therapy for the treatment of recurrent glioblastoma multiforme with the Yale University Comprehensive Cancer Center.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/06/17 | $26,100,000 | Series A |
Novartis Venture Funds | undisclosed |
